Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Why the study?
Does candesartan plus hydrochlorothiazide reduce major cardiovascular events in intermediate-risk persons without cardiovascular disease?
Population
Persons at intermediate risk who did not have cardiovascular disease
Comparison
Candesartan 16 mg per day plus… vs Placebo
Design
RCT
Authors
Discussion
Loading...
Member takes
Implication
No benefit from candesartan-HCTZ for primary prevention in intermediate-risk persons without CVD; challenges assumptions of event reduction with this BP-lowering approach.
Structured PICO
Does candesartan plus hydrochlorothiazide reduce major cardiovascular events in intermediate-risk persons without cardiovascular disease?
P
Population
Persons at intermediate risk who did not have cardiovascular disease
I
Intervention
Candesartan 16 mg per day plus hydrochlorothiazide 12.5 mg per day
C
Comparator
Placebo
O
Outcome
Major cardiovascular eventscomposite
In intermediate-risk persons without cardiovascular disease, blood pressure lowering with candesartan and hydrochlorothiazide did not reduce major cardiovascular events compared to placebo.
Cite This Study
Lonn et al. (2016) studied this question.